LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Home・Akciju saraksts・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Slēgts

SektorsVeselības aprūpe

35.26 -0.45

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

35.08

Max

35.52

Galvenie mērījumi
By Trading Economics
Ienākumi	11M 51M
Pārdošana	39M 239M
P/E Sektora vidējais	11.126 79.874
EPS	1.08
Peļņas marža	21.242
Darbinieki	268
EBITDA	14M 73M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+29.36% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	344M 2B
Iepriekšējā atvēršanas cena	35.71
Iepriekšējā slēgšanas cena	35.26

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bullish Evidence

29.8 / N/A Atbalsts un pretestība

Harmony Biosciences Holdings Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 28. nov. 15:29 UTC

Galvenie tirgus virzītāji

Iegādes, apvienošanās, pārņemšana

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

2025. g. 28. nov. 21:50 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 28. nov. 19:59 UTC

Tirgus saruna

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

2025. g. 28. nov. 19:47 UTC

Tirgus saruna

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

2025. g. 28. nov. 18:16 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 28. nov. 18:16 UTC

Tirgus saruna

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

2025. g. 28. nov. 18:08 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 28. nov. 18:08 UTC

Tirgus saruna

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

2025. g. 28. nov. 17:48 UTC

Tirgus saruna

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

2025. g. 28. nov. 17:20 UTC

Tirgus saruna

Auto & Transport Roundup: Market Talk

2025. g. 28. nov. 16:50 UTC

Iegādes, apvienošanās, pārņemšana

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

2025. g. 28. nov. 15:51 UTC

Tirgus saruna

Canada Household Spending Edges Lower -- Market Talk

2025. g. 28. nov. 15:33 UTC

Tirgus saruna

Crude Futures Gain as U.S. Market Reopens -- Market Talk

2025. g. 28. nov. 15:21 UTC

Tirgus saruna

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

2025. g. 28. nov. 15:13 UTC

Tirgus saruna

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

2025. g. 28. nov. 15:11 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 28. nov. 15:11 UTC

Tirgus saruna

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

2025. g. 28. nov. 14:51 UTC

Tirgus saruna

Canada GDP Report Masks Fragile State of Economy -- Market Talk

2025. g. 28. nov. 14:41 UTC

Tirgus saruna

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

2025. g. 28. nov. 14:37 UTC

Tirgus saruna

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

2025. g. 28. nov. 14:33 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 28. nov. 14:33 UTC

Tirgus saruna

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

2025. g. 28. nov. 14:20 UTC

Tirgus saruna

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

2025. g. 28. nov. 14:10 UTC

Tirgus saruna

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

2025. g. 28. nov. 13:39 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 28. nov. 13:39 UTC

Tirgus saruna

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

2025. g. 28. nov. 13:36 UTC

Tirgus saruna

Canada's Economy Expands More Than Expected -- Market Talk

2025. g. 28. nov. 13:29 UTC

Tirgus saruna

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

2025. g. 28. nov. 13:27 UTC

Tirgus saruna

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

2025. g. 28. nov. 13:19 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Harmony Biosciences Holdings Inc Prognoze

Cenas mērķis

By TipRanks

29.36% augšup

Prognoze 12 mēnešiem

Vidējais 46 USD 29.36%

Augstākais 62 USD

Zemākais 32 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Harmony Biosciences Holdings Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

29.8 / N/AAtbalsts un pretestība

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.